RE:The burden on JAZZ to prove that LABS violatedExclusivity ends on Sativex in Europe summer 2023....Exclusivity ends for Epidiolex on one "indication summer 2023...patent challenge this Wednesday possible...it appears the FDA gives exclusivity rights/patents for each individual " indication"...ie..illness for treatment...also if "exclusivity" has ended and a generic is approved a Corp may claim patent infringement in the U.S which brings an automatic 30 month stay on the generic....the question is if the patent was broken through a challenge can they still file for patent infringement and would a 30 month stay still be imposed....this is U.S only.....the "NDA with a Traditional Pharmaceutical Company in the U.K may very well be a Sativex generic for Europe.